$BSX Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.73 down -2.67% YoY
• Reported revenue of $5.14B up 1.44% YoY
• Boston Scientific estimates FY2026 reported and organic sales growth of approximately 4.25% and 3.75%, with adjusted EPS $3.16 to $3.18; Q4 reported and organic sales decline (3.0)% to (1.0)%, with adjusted EPS $0.77 to $0.79.